Duke University biomedical engineers have developed a new delivery system that overcomes the shortcomings of a promising class of peptide drugs -- very small proteins -- for treating diseases such as diabetes and cancer.
Duke University biomedical engineers have developed a new delivery system that overcomes the shortcomings of a promising class of peptide drugs -- very small proteins -- for treating diseases such as diabetes and cancer.
